In the paper, the researchers conducted blood tests on a few dozen people and found that the presence of pre-existing adaptive immune responses in humans to either
Cas9 homolog «may hinder the safe and efficacious use of the Cas9 / gRNA system to treat disease, and may even result in significant toxicity to patients.»